Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye disease, with a clinic entry planned by end of 2026.
A biotech backed by Atlas Venture and Medicxi uncloaked on Wednesday morning to tackle the related autoimmune conditions Graves’ disease and thyroid eye disease, and …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder - Alterity
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
Why Is TG Therapeutics Stock Gaining Tuesday? - TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics Stock Is Surging Today: What's Driving The Action? - TG Therapeutics (NASDAQ:TGTX)
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
City banks nearly $100M for next-gen RNAi drugs
AbTherx Expands Platform and Leadership Team to Unlock Antibody Discovery for Multispecifics, Enzymes, GPCRs, and Ion Channels
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit…
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a |…
The medications most likely to cause thyroid eye disease are alemtuzumab, certain immune checkpoint inhibitors, amiodarone and…
City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond…
GSK’s recent deal to license out a rare liver disease drug just got sweeter.
Alterity Therapeutics advances ATH434 toward Phase 3 after FDA alignment on trial design for MSA, while shares decline in…
